|
|
Post by uvula on Sept 1, 2021 21:50:14 GMT -5
If you had some play money, which one of these 3 companies would you buy shares of?
|
|
|
|
Post by porkini on Sept 1, 2021 22:08:20 GMT -5
Yes.
Edit:
Oh, wait, I thought that was mnkd, not sure what "mbkd" is, got nothing on that one ("mbkd").
Edit edit:
I've got positions in all three, largest in mnkd (assuming "mnkd" is what you meant) with comparatively small positions in the other two.
|
|
|
|
Post by uvula on Sept 1, 2021 22:13:46 GMT -5
Darn. The thread name seems to be uneditable.
Edit: Thank you dear moderator for fixing my thread name typo.
|
|
|
|
Post by prcgorman2 on Sept 1, 2021 22:33:08 GMT -5
Actually, just sold a few “extra” shares of MNKD and made a token purchase of NRXP last week. It’s moved about $2.30 since then. Should have sold/bought more I guess.
|
|
|
|
Post by longliner on Sept 1, 2021 23:45:08 GMT -5
Actually, just sold a few “extra” shares of MNKD and made a token purchase of NRXP last week. It’s moved about $2.30 since then. Should have sold/bought more I guess. Our day is near. I too have a small positions in NRXP. |
|
|
|
Post by Clement on Sept 2, 2021 6:15:52 GMT -5
UTHR - I think this one will grow like a big tech stock.
MNKD - IF Tyvaso DPI is approved as expected, mnkd will grow even more in 12 - 24 months.
NRXP - I do not own nxrp because IP of aviptadil seems confusing. Could someone help me out on this?
|
|
|
|
Post by boca1girl on Sept 2, 2021 6:25:39 GMT -5
I just bought a few shares of nrxp. It should have a big pop with an EUA but I believe MNKD will have a much bigger return over time.
|
|
|
|
Post by peppy on Sept 2, 2021 6:28:20 GMT -5
|
|
|
|
Post by prcgorman2 on Sept 2, 2021 6:35:23 GMT -5
It sounds like the IPR is owned by Relief, and there is a development agreement with NRXP. And the agreement between NRXP and MNKD to develop an inhaled version (versus current intravenous administration) is not excluded by the development agreement between NRXP and Relief. I expect there is a possibility Relief is a party to the agreement between NRXP and MNKD or that Relief is otherwise compensated for commercialization using other methods of administration. |
|
|
|
Post by Clement on Sept 2, 2021 6:38:04 GMT -5
My concern is, after NRXP does all the hard work of getting EUA, some big pharma will swoop in with a new formulation of VIP and offer stiff competition in the intermediate future. How likely/unlikely is that? |
|
|
|
Post by peppy on Sept 2, 2021 6:53:26 GMT -5
My concern is, after NRXP does all the hard work of getting EUA, some big pharma will sweep in with a new formulation of VIP and offer stiff competition in the intermediate future. How likely/unlikely is that? I looked at the FDA calendar. The big names are there. We know how it works. www.fdatracker.com/fda-calendar/Reports this am that hospital cases in florida are going down. When ask for an explanation, She said, the monoclonal antibody station set up around the state seem to be having an impact. One more thing regarding NRXP, the shares issued are but a portion of the shares. I have it in a post somewhere, probably off topic. |
|
|
|
Post by dh4mizzou on Sept 2, 2021 7:05:13 GMT -5
"One more thing regarding NRXP, the shares issued are but a portion of the shares."
Peppy, please explain.
|
|
|
|
Post by peppy on Sept 2, 2021 7:06:48 GMT -5
"One more thing regarding NRXP, the shares issued are but a portion of the shares." Peppy, please explain. ok, but I have to dig... I'll be back. |
|
|
|
Post by peppy on Sept 2, 2021 7:24:45 GMT -5
"One more thing regarding NRXP, the shares issued are but a portion of the shares." Peppy, please explain. ok, but I have to dig... I'll be back. Found it. NRXP will make money either way, 3 IV's over 12 hours, or technosphere aviptadil. I saw NRXP share price moving earlier. MNKD, the formulation and all. + we discovered that the original RLF-100 formulation and manufacturing method had only a few weeks of stability, leaving hospitals unable to stock the investigational medicine in pharmacies, and leaving aviptadil out of consideration for national strategic stockpiles. + the successful new formulation and production scaleup of ZYESAMI permits it to relaunch the Expanded Access and Right to Try campaigns. +“We began this project a year ago, with 9 days of stability and an ability to manufacture about 100 doses of medicine each day. We learned through significant study and testing that the important biologic activity of this small peptide is accompanied by a fragile molecular structure that is destroyed by standard high-volume pharmaceutical manufacturing processes.” 100,000,000 shares authorized; 2,688,242 shares issued and outstandingadded, Shares Outstanding 51.33 M Public Float 17.88 M |
|
|
|
Post by dh4mizzou on Sept 2, 2021 7:27:37 GMT -5
Peppy, thanks. But that's pretty standard right? All companies have authorized shares that are "in the bank" so to speak. I was getting the impression that you were implying that a major dilution was upcoming.
|
|
